Advancing adjuvants: what’s new & what’s next in vaccine formulation?

GSK’s Derek O’Hagan shares his thoughts on the evolution of adjuvants, the importance of systems vaccinology, and the road ahead for RNA vaccines.

Derek O’Hagan is Senior Advisor Vaccines R&D and GSK Fellow at GSK. He is a qualified pharmacist and former academic researcher, who has worked on vaccine delivery and adjuvants in the pharmaceutical industry since 1993. In the mid 1990s, he worked on the novel emulsion adjuvant MF59, which is now included in a licensed flu vaccine in more than 40 countries. Prior to joining GSK, he was Global Head of Vaccine Chemistry and Formulation Research for Novartis Vaccines and was part of the team that established the Novartis program on self-amplifying RNA vaccines, now active in GSK. He has served on the Board of Scientific Advisors for the Controlled Release Society and is a Fellow of the American Association of Pharmaceutical Scientists.

Please enter your email to access content Read now